| Revenue guidance | 14.0% → 16.0% Raised by 2.0 percentage points |
|---|---|
| Management target | Revenue 16.0% FY27 |
| Revenue growth | 22.8% YoY growth, heavily supported by international and ARV segments. |
|---|---|
| Margins | EBITDA margin up 50 bps to 19.7% through operating efficiencies. |
| Demand visibility | Strong international order book; domestic recovery expected through H2. |
| Management confidence | High; confident in organizational changes and domestic acceleration in H2. |
Growth
Revenue grew 22.8% YoY; International markets surged 34.2% while India organic growth lagged at 6-8%.
Outlook
Management maintains guidance of mid-teen revenue growth and 70-100 bps EBITDA margin expansion for FY27.
Risks
Domestic growth remains subdued during the 'Zoventus' restructuring phase; gross margins pressured by business mix.
Last quarter's promises, checked
Delivered
- Guided mid-teens FY26 revenue growth → delivered 20.4% YoY (= BEAT)
- Guided ~100 bps EBITDA margin expansion → delivered +110 bps (= BEAT)
- Guided healthy double-digit India growth → delivered 15.4% (= BEAT)
Partly delivered
- Guided ~60% gross margin → delivered 59.3% (= PARTIAL)
Earnings Call Transcript filed with BSE, NSE: EMCURE. Summary written with AI assistance from the document.
Emcure Pharmaceuticals Ltd: key numbers
- Share price
- ₹1,918.00
- Market cap
- ₹36,386 Cr
- Revenue (annual)
- ₹9,204 Cr
- Net profit (annual)
- ₹924.4 Cr
- P/E (TTM)
- 36.0×Sector 47.3×
- Promoter holding
- 77.83%-0.04% QoQ
- FII holding
- 4.87%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Emcure Pharmaceuticals Ltd
All →Emcure Pharmaceuticals Investor Presentation: Key Takeaways
Emcure reported strong Q1 FY27 momentum with revenue of INR 92,035 Mn and PAT of INR 9,413 Mn for FY26. Strategy focuses on chronic-led domestic expansion and differentiated international portfolios.
Emcure Pharmaceuticals Annual General Meeting
Emcure Pharmaceuticals held its 45th Annual General Meeting on September 21, 2026. The meeting transacted ordinary and special business, including the approval of a final dividend.
Emcure Pharmaceuticals Employee Stock Options
Emcure Pharmaceuticals allotted 11,400 equity shares to employees following the exercise of vested options under the ESOP scheme. This increases the company's total issued share capital.
Emcure Pharmaceuticals Credit Rating
Emcure Pharmaceuticals received a credit rating reaffirmation from CARE Ratings for its existing bank facilities. The company maintains its stable outlook and financial profile.
Emcure Pharmaceuticals Other Announcement
Emcure Pharmaceuticals has filed its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26 as part of its Annual Report.
Emcure Pharmaceuticals Annual General Meeting
Emcure Pharmaceuticals has issued a notice for its 45th Annual General Meeting to be held on September 21, 2026. The meeting will address financial statements, dividends, and directorship appointments.